Explorative study regarding influenza vaccine hesitancy among HIV-infected patients.
HIV
Influenza vaccine
Italy
at-risk group immunization
vaccine hesitancy
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
30 11 2022
30 11 2022
Historique:
pubmed:
1
4
2022
medline:
15
6
2022
entrez:
31
3
2022
Statut:
ppublish
Résumé
There are scarce data regarding influenza vaccination among people with HIV infection (PWHIV). The goal of this explorative study is to assess hesitancy toward influenza vaccination in a group of PWHIV during the COVID-19 pandemic. A questionnaire was administered to 219 patients vaccinated at our clinic during the 2020-2021 campaign. It evaluated subjects' adherence to influenza vaccine over the last three seasonal vaccination campaigns, vaccine confidence, complacency and convenience, and the effect of the pandemic on the choice to become vaccinated. The population was divided into two groups: fully adherent to influenza vaccine (all three campaigns, 117 patients) and non-fully adherent (one or two campaigns, 102 patients). Adherence increased in the non-fully adherent group in 2020-2021, but the pandemic did not affect the choice. Misbeliefs emerged: the influenza vaccine was considered protective against SARS-CoV-2 (22.8% of the total population); almost half of all patients thought the influenza vaccine could improve their CD4 T cell level (57.3% in fully adherent, 40.2% in non-fully adherent, p < .05). In 2020-2021 campaign, three quarters of the non-fully adherent group would not have been vaccinated in a location other than our clinic (75.5% vs. 88.9% in the fully adherent group, p < .05). Conclusively, offering a secure and private space for vaccination against influenza seems to encourage vaccination; healthcare professionals should improve counseling to increase adherence and correct misbeliefs.
Identifiants
pubmed: 35357270
doi: 10.1080/21645515.2022.2046434
pmc: PMC9196753
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2046434Références
HIV Med. 2020 Nov;21(10):617-624
pubmed: 32885559
Vaccine. 2021 Oct 1;39(41):6081-6087
pubmed: 34521551
Vaccine. 2021 Aug 31;39(37):5271-5276
pubmed: 34376307
Vaccine. 2021 Sep 24;39(40):5737-5740
pubmed: 34456072
Expert Rev Respir Med. 2016 Apr;10(4):463-472
pubmed: 26918376
Vaccines (Basel). 2020 Nov 30;8(4):
pubmed: 33266212
Int J Environ Res Public Health. 2021 Jul 29;18(15):
pubmed: 34360345
Vaccine. 2015 Aug 14;33(34):4191-203
pubmed: 25896385
Vaccine. 2011 Apr 12;29(17):3183-91
pubmed: 21371580
Front Med (Lausanne). 2021 Jun 25;8:681469
pubmed: 34249971
PLoS One. 2015 Mar 18;10(3):e0118884
pubmed: 25786103
Hum Vaccin Immunother. 2021 May 4;17(5):1420-1425
pubmed: 32991221
BMC Infect Dis. 2006 Mar 30;6:65
pubmed: 16571140
Lancet Infect Dis. 2009 Aug;9(8):493-504
pubmed: 19628174
Hum Vaccin Immunother. 2015;11(1):263-9
pubmed: 25483544
Clin Diabetes. 2015 Jul;33(3):116-22
pubmed: 26203204
Isr Med Assoc J. 2000 Dec;2(12):902-7
pubmed: 11344771
PLoS One. 2021 Aug 12;16(8):e0256040
pubmed: 34383834
Vaccine. 2021 Feb 22;39(8):1187-1189
pubmed: 33309482
J Am Geriatr Soc. 2004 Jan;52(1):25-30
pubmed: 14687311
Hum Vaccin Immunother. 2018 Mar 4;14(3):772-789
pubmed: 28787234
Vaccine. 2018 Jun 18;36(26):3861-3867
pubmed: 29605516
Hum Vaccin Immunother. 2020;16(1):95-99
pubmed: 31339794
Dis Markers. 2017;2017:5729639
pubmed: 28694558
Vaccines (Basel). 2021 Feb 18;9(2):
pubmed: 33670661
Vaccines (Basel). 2020 Sep 25;8(4):
pubmed: 32992864
Brain Sci. 2021 Jul 05;11(7):
pubmed: 34356125